Paper Details

  1. Home
  2. Paper Details

Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.

Author: HamasakiToshimitsu, HisamatsuTakeshi, KawanoMahiru, KimuraTadashi, KishimotoToshiko, MabuchiSeiji, MatsumotoYuri, SasanoTomoyuki, SawadaKenjiro, TakahashiKazuhiro, TakahashiRyoko, TakahashiToshifumi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Combination treatment with trabectedin and SN-38 displays the greatest cytotoxic effect against ovarian CCC.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: The objective of this study was to investigate the chemotherapeutic agents that produce the strongest synergistic effects when combined with trabectedin against ovarian clear cell carcinoma (CCC), which is regarded as an aggressive chemoresistant histological subtype. METHODS: Using 4 h...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/24844217

データ提供：米国国立医学図書館（NLM）

Ovarian Clear Cell Carcinoma: A New Oasis in the Desert of Treatment

Ovarian clear cell carcinoma, a type of ovarian cancer, can be particularly aggressive and resistant to traditional chemotherapy. This research delves into the potential of combining trabectedin with other chemotherapeutic agents, like a desert traveler seeking a more effective route through a challenging landscape. The authors explored the synergistic effects of combining trabectedin with irinotecan or topotecan, aiming to find a more powerful weapon against this formidable foe.

Trabectedin Plus SN-38: A New Route Through the Desert

The study found that combining trabectedin with SN-38 (the active metabolite of irinotecan) resulted in the most potent cytotoxic effect against ovarian clear cell carcinoma. This combination demonstrated synergistic effects, suggesting a more powerful approach to treatment. This discovery could offer a new route through the desert of ovarian cancer treatment, offering a glimmer of hope for patients.

Navigating the Desert of Ovarian Cancer: Finding the Right Path

Ovarian cancer treatment can be a complex and challenging journey. This research provides a promising new path by exploring the synergistic effects of combining different chemotherapeutic agents. The discovery of the effectiveness of trabectedin plus SN-38 offers a potential new oasis in the desert of ovarian cancer treatment, providing hope for a more successful outcome.

Dr.Camel's Conclusion

This research offers a promising new route through the desert of ovarian clear cell carcinoma treatment. The combination of trabectedin with SN-38 demonstrates a powerful synergistic effect, potentially leading to more effective treatment outcomes. This discovery could offer a much-needed oasis in the fight against this aggressive form of cancer.

Date :
  1. Date Completed 2015-01-09
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

24844217

DOI: Digital Object Identifier

00009577-201406000-00004

Related Literature

Article Analysis
・Effects of topotecan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.